Cimetidine - Revision history

Elcatracho: /* See Also */

2021-03-07T22:30:10Z

SeanDenny: /* Common */

2020-12-10T00:08:48Z

Common

← Older revision		Revision as of 00:08, 10 December 2020
Line 61:		Line 61:

	===Common===		===Common===
	*[[~~headche~~]]		*[[headache]]
	*[[diarrhea]]		*[[diarrhea]]
	*[[dizziness]]		*[[dizziness]]

Fletc151: /* References */

2019-06-08T18:55:55Z

References

← Older revision		Revision as of 18:55, 8 June 2019
Line 83:		Line 83:

	==References==		==References==
			*2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-694. doi: 10.1111/jgs.15767. [PubMed 30693946]
			*American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Anesthesiology. 2007;106(4):843-863. [PubMed 17413923]
			*Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med. 1999;246(3):247-252. [PubMed 10475992]
			*ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;56(4):347-379. [PubMed 10690219]
			*Aronoff GR, Bennett WM, Berns JS, et al, eds. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007.

	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Mholtz: Text replacement - "* " to "*"

2017-07-14T21:55:30Z

Text replacement - "* " to "*"

← Older revision		Revision as of 21:55, 14 July 2017
Line 58:		Line 58:
	*[[tachycardia]]		*[[tachycardia]]
	*[[AV block]]		*[[AV block]]
	* skin reaction		*skin reaction

	===Common===		===Common===

Mholtz at 06:29, 13 July 2017

2017-07-13T06:29:43Z

← Older revision		Revision as of 06:29, 13 July 2017
Line 83:		Line 83:

	==References==		==References==
			<references/>

	~~<references/>~~
	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Rossdonaldson1 at 20:50, 22 January 2017

2017-01-22T20:50:41Z

← Older revision		Revision as of 20:50, 22 January 2017
Line 5:		Line 5:

	==Adult Dosing==		==Adult Dosing==
			===Duodenal Ulcer, Active===
			*800mg PO QHS x 4-8 weeks

	Duodenal Ulcer, ~~Active: 800mg~~ PO QHS ~~x 4-8 weeks~~		===Duodenal Ulcer, Maintenance===
			*400mg PO QHS

	~~Duodenal~~ Ulcer, ~~Maintenance: 400mg~~ PO QHS		===Gastric Ulcer, active benign===
			*800mg PO QHS x 6 weeks

	~~Gastric Ulcer, active benign: 800mg PO QHS x 6 weeks~~		===H. Pylori Infection===
			*400mg PO BID x 10-28 days
	H. Pylori Infection: 400mg PO BID x 10-28 days

	==Pediatric Dosing==		==Pediatric Dosing==
			===GERD/PUD===
			*Neonates: 5- 10mg/kg/day PO divided q8-12h
	GERD/PUD:		*Infants: 10-20mg/kg/day PO divided q8-12h
	*Neonates: 5- 10mg/kg/day PO divided q8-12h		*Children: 20-40mg/kg/day PO divided q6H
	*Infants: 10-20mg/kg/day PO divided q8-12h
	*Children: 20-40mg/kg/day PO divided q6H

	==Special Populations==		==Special Populations==
Line 34:		Line 35:
	==Contraindications==		==Contraindications==
	*Allergy to class/drug		*Allergy to class/drug
	- caution if renal impairment		*caution if renal impairment
	- caution if hepatic impairment		*caution if hepatic impairment
	- caution in elderly patients		*caution in elderly patients
	- caution if chronic pulmonary disease		*caution if chronic pulmonary disease
	- caution if DM		*caution if [[DM]]
	- caution if immunocompromised		*caution if immunocompromised

	==Adverse Reactions==		==Adverse Reactions==
	===Serious===		===Serious===
	- neutropenia		*[[Anticholinergic toxicity]]
	- thrombocytopenia		*[[neutropenia]]
	- agranulocytosis		*[[thrombocytopenia]]
	- aplastic anemia		*agranulocytosis
	- pneumonia		*aplastic anemia
	-depression		*[[pneumonia]]
	-psychosis		*[[depression]]
	-hallucinations		*[[psychosis]]
	-pancreatitis		*[[hallucinations]]
	-interstital nephritis		*[[pancreatitis]]
	-bradycardia		*interstital nephritis
	-tachycardia		*[[bradycardia]]
	-AV block		*[[tachycardia]]
	- skin reaction		*[[AV block]]
			* skin reaction

	===Common===		===Common===
	-headche		*[[headche]]
	-diarrhea		*[[diarrhea]]
	-dizziness		*[[dizziness]]
	-gynecomastia		*gynecomastia
	-nausea		*[[nausea]]
	-vomiting		*[[vomiting]]
	-confusion		*confusion
	-agitation		*agitation
	-drowsiness		*drowsiness
	-rash		*[[rash]]
	-ALT,AST elevation		*ALT,AST elevation

	==Pharmacology==		==Pharmacology==
Line 78:		Line 80:

	==See Also==		==See Also==
			*[[Anticholinergic toxicity]]

	==References==		==References==

Neil.m.young: Text replacement - "0 mg" to "0mg"

2016-07-20T00:52:04Z

Text replacement - "0 mg" to "0mg"

← Older revision		Revision as of 00:52, 20 July 2016
Line 1:		Line 1:
	==General==		==General==
	*Type: [[H2 blocker]]		*Type: [[H2 blocker]]
	*Dosage Forms: 200, 300, 400, ~~800 mg~~		*Dosage Forms: 200, 300, 400, 800mg
	*Common Trade Names: Tagamet HB 200		*Common Trade Names: Tagamet HB 200

	==Adult Dosing==		==Adult Dosing==

	Duodenal Ulcer, Active: ~~800 mg~~ PO QHS x 4-8 weeks		Duodenal Ulcer, Active: 800mg PO QHS x 4-8 weeks

	Duodenal Ulcer, Maintenance: ~~400 mg~~ PO QHS		Duodenal Ulcer, Maintenance: 400mg PO QHS

	Gastric Ulcer, active benign: ~~800 mg~~ PO QHS x 6 weeks		Gastric Ulcer, active benign: 800mg PO QHS x 6 weeks

	H. Pylori Infection: ~~400 mg~~ PO BID x 10-28 days		H. Pylori Infection: 400mg PO BID x 10-28 days

	==Pediatric Dosing==		==Pediatric Dosing==
Line 18:		Line 18:

	GERD/PUD:		GERD/PUD:
	*Neonates: 5- ~~10 mg~~/kg/day PO divided q8-12h		*Neonates: 5- 10mg/kg/day PO divided q8-12h
	*Infants: 10-~~20 mg~~/kg/day PO divided q8-12h		*Infants: 10-20mg/kg/day PO divided q8-12h
	*Children: 20-~~40 mg~~/kg/day PO divided q6H		*Children: 20-40mg/kg/day PO divided q6H

	==Special Populations==		==Special Populations==

Neil.m.young: Text replacement - "* " to "*"

2016-07-08T02:59:48Z

Text replacement - "* " to "*"

← Older revision		Revision as of 02:59, 8 July 2016
Line 18:		Line 18:

	GERD/PUD:		GERD/PUD:
	* Neonates: 5- 10 mg/kg/day PO divided q8-12h		*Neonates: 5- 10 mg/kg/day PO divided q8-12h
	* Infants: 10-20 mg/kg/day PO divided q8-12h		*Infants: 10-20 mg/kg/day PO divided q8-12h
	* Children: 20-40 mg/kg/day PO divided q6H		*Children: 20-40 mg/kg/day PO divided q6H

	==Special Populations==		==Special Populations==

Neil.m.young: Text replacement - "==Sources==" to "==References=="

2016-06-26T10:35:05Z

Text replacement - "==Sources==" to "==References=="

← Older revision		Revision as of 10:35, 26 June 2016
Line 79:		Line 79:
	==See Also==		==See Also==

	==~~Sources~~==		==References==

	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Ostermayer: Text replacement - "Category:Drugs" to "Category:Pharmacology"

2016-03-22T15:54:51Z

Text replacement - "Category:Drugs" to "Category:Pharmacology"

← Older revision		Revision as of 15:54, 22 March 2016
Line 82:		Line 82:

	<references/>		<references/>
	[[Category:~~Drugs~~]]		[[Category:Pharmacology]]

← Older revision		Revision as of 22:30, 7 March 2021
Line 80:		Line 80:

	==See Also==		==See Also==
			*[[Antihistamines]]
	*[[Anticholinergic toxicity]]		*[[Anticholinergic toxicity]]